Maia Pharmaceuticals
As of the edition of 20 October 2026, Maia Pharmaceuticals runs 4 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bortezomib | none listed | 1 |
| Daptomycin | none listed | 0 |
| Bivalirudin | none listed | 0 |
| Sincalide | none listed | 1 |
A route B row is one company at one target.